Anthropic 推出 Claude Science：面向药物开发与计算生物学的自主 AI 产品
英文摘要
Anthropic announced Claude Science, a new flagship product for scientific research that can autonomously write and execute code on computer clusters, with a focus on computational biology and drug discovery. It is available to all paid Claude subscribers and was demonstrated identifying drug candidates for phenylketonuria. The product emphasizes reproducibility and integrates with genetics and chemistry tools. Anthropic will also use Claude Science to pursue its own research into drugs for rare, neglected diseases. The launch positions it alongside Claude Code and Claude Cowork as a major commercial offering, targeting pharmaceutical and biotech firms.
中文摘要
Anthropic 发布了全新旗舰产品 Claude Science，可自主在计算集群上编写并运行代码，专注于计算生物学和药物发现。该产品已面向所有付费 Claude 用户开放，并在演示中识别出苯丙酮尿症的候选药物。Claude Science 强调可复现性，能与遗传学和化学工具对接。Anthropic 还将用该产品自行开展针对罕见病药物的研究。此次发布使其与 Claude Code、Claude Cowork 并列成为重要商用产品，瞄准制药和生物技术市场。
关键要点
Claude Science is a new standalone product from Anthropic, available to all paid Claude subscribers, ranked alongside Claude Code and Claude Cowork as a flagship offering.
Claude Science 是 Anthropic 新推出的独立产品，向所有付费 Claude 用户开放，与 Claude Code、Claude Cowork 并列为旗舰级产品。
The agent can autonomously write and run code on powerful computer clusters, interface with scientific software and databases, and prioritizes reproducibility for computational biology workflows.
该智能体可自主在计算集群上编写并运行代码，对接科学软件和数据库，并优先保障计算生物学工作流的可复现性。
A live demonstration showed Claude Science autonomously identifying new drug candidates for the rare genetic disease phenylketonuria.
现场演示中，Claude Science 自主识别出了罕见遗传病苯丙酮尿症的多个新候选药物。
Anthropic plans to use Claude Science internally for drug research into rare, neglected diseases, aiming to evaluate the product’s real-world effectiveness.
Anthropic 计划将 Claude Science 用于公司内部的罕见病药物研究，以评估产品的实际效能。
The product is explicitly marketed to pharmaceutical executives and biotech founders, potentially leading to high-value enterprise contracts as the company approaches profitability and an expected IPO.
产品明确面向制药高管和生物技术创始人推广，在公司接近盈利和预计上市之际，或带来丰厚的企业合同。